Success Metrics

Clinical Success Rate
66.7%

Based on 4 completed trials

Completion Rate
67%(4/6)
Active Trials
0(0%)
Results Posted
75%(3 trials)
Terminated
2(25%)

Phase Distribution

Ph phase_3
3
38%
Ph phase_2
1
13%
Ph phase_4
2
25%
Ph not_applicable
2
25%

Phase Distribution

0

Early Stage

1

Mid Stage

5

Late Stage

Phase Distribution8 total trials
Phase 2Efficacy & side effects
1(12.5%)
Phase 3Large-scale testing
3(37.5%)
Phase 4Post-market surveillance
2(25.0%)
N/ANon-phased studies
2(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

57.1%

4 of 7 finished

Non-Completion Rate

42.9%

3 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Active(1)
Completed(4)
Terminated(3)

Detailed Status

Completed4
Terminated2
Not yet recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
66.7%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (12.5%)
Phase 33 (37.5%)
Phase 42 (25.0%)
N/A2 (25.0%)

Trials by Status

not_yet_recruiting113%
terminated225%
completed450%
withdrawn113%

Recent Activity

0 active trials
Showing 5 of 8
not_yet_recruitingphase_3

Effect of Intravenously Iron Infusion on the Prevention and Treatment of Anemia in Ovarian Cancer

NCT06248749
completedphase_2

Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment

NCT01414075
terminatednot_applicable

Artificial Intelligence for Optimal Anemia Management in End-stage Renal Disease: The Anemia Control Model (ACM) Trial

NCT03214627
withdrawnphase_4

A Randomized Study to Compare the Dosing Schedule of INFeD in Anemic Patients.

NCT03286205
completedphase_3

A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis

NCT02504294
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT06248749Phase 3

Effect of Intravenously Iron Infusion on the Prevention and Treatment of Anemia in Ovarian Cancer

Not Yet Recruiting
NCT01414075Phase 2

Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment

Completed
NCT03214627Not Applicable

Artificial Intelligence for Optimal Anemia Management in End-stage Renal Disease: The Anemia Control Model (ACM) Trial

Terminated
NCT03286205Phase 4

A Randomized Study to Compare the Dosing Schedule of INFeD in Anemic Patients.

Withdrawn
NCT02504294Phase 3

A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis

Completed
NCT02631980Phase 3

HepciFer Study: Hepcidin Overexpression After Hepatectomy : Does Iron Supplementation Make Sense ?

Completed
NCT00830037Phase 4

A Clinical Trial of Oral Versus IV Iron in Patients With Chronic Kidney Disease

Terminated
NCT02107053Not Applicable

The Effect of Pomegranate Juice (PJ) on Oxidative Stress Biomarkers During Treatment With IV Iron During One Dialysis Session

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8